Those who invested in Alnylam Pharmaceuticals (NASDAQ:ALNY) five years ago are up 63%

Wall Street Analysts Are Bullish on Top Healthcare Picks

Buy Rating Affirmed for Alnylam Pharmaceuticals on Strong Commercial Business and Expanding CNS Pipeline

Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?

Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session

Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease

Pharma Stock Roundup: NVO's New Obesity Pill Data, RHHBY, AZN's Pipeline Updates

Analysts Are Bullish on Top Healthcare Stocks: DarioHealth (DRIO), United Therapeutics (UTHR)

Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal

Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal

Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alnylam Pharma (ALNY) and IO Biotech (IOBT)

Buy Rating Affirmed for Alnylam Pharma as Zilebesiran Shows Blockbuster Potential

Buy Rating Affirmed for Alnylam Pharma Amid Positive Clinical Trials and Strategic Collaborations

Roche, Alnylam say blood pressure drug succeeds in mid-stage trial

Roche, Alnylam say blood pressure drug succeeds in mid-stage trial

Alnylam, Roche blood pressure drug scores in second mid-stage trial

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives